UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Metabolic bone disease in primary biliary cholangitis (primary biliary cirrhosis)

Authors
Steven Flamm, MD
Raoul Poupon, MD
Section Editors
Clifford J Rosen, MD
Keith D Lindor, MD
Deputy Editor
Anne C Travis, MD, MSc, FACG, AGAF

INTRODUCTION

Hepatic osteodystrophy refers to the structural and metabolic bone changes seen in patients with chronic liver disease and includes both osteoporosis and osteomalacia. Osteoporosis is a skeletal condition characterized by low bone mass, whereas osteomalacia is a disorder of decreased mineralization of newly formed osteoid at sites of bone turnover. Both disorders put patients at risk for fractures. (See "Pathogenesis of osteoporosis" and "Epidemiology and etiology of osteomalacia" and "Clinical manifestations, diagnosis, and treatment of osteomalacia".)

This topic will review metabolic bone disease in patients with primary biliary cholangitis (previously referred to as primary biliary cirrhosis). The discussion that follows is consistent with the 2003 guidelines issued by The American Gastroenterological Association (AGA) regarding osteoporosis in patients with liver disease [1,2].

Other issues related to metabolic bone disease, including metabolic bone disease following liver transplantation and a detailed discussion of treatment approaches for osteoporosis, are discussed elsewhere. (See "Osteoporosis after solid organ or stem cell transplantation" and "Overview of the management of osteoporosis in postmenopausal women" and "Evaluation and treatment of premenopausal osteoporosis" and "Treatment of osteoporosis in men".)

EPIDEMIOLOGY

Estimates of the prevalence of osteoporosis among patients with primary biliary cholangitis (PBC) range from 14 to 52 percent [3]. One reason that osteoporosis is common in PBC is that many patients with PBC are postmenopausal women, a group already at increased risk for osteoporosis. In addition to age and postmenopausal status, other factors associated with an increased risk for osteoporosis among patients with PBC include lower weight, shorter height, more advanced fibrosis on liver biopsy, hypogonadism, and increasing severity and duration of PBC [3-7]. The prevalence of osteoporosis appears to be decreasing over time, likely related to improved treatment for PBC. In one study, the prevalence of osteoporosis between 1987 and 1995 was 37 percent, whereas between 2002 and 2007 it was 21 percent, though the difference did not reach statistical significance.

Osteoporosis has been shown to be a risk factor for vertebral and nonvertebral fractures in women with PBC [6], and the prevalence of fractures among patients with PBC is approximately 10 to 20 percent [2]. In a study of 185 women with PBC, fractures were seen in 21 percent. Risk factors for fractures included osteoporosis, menopause, age, and height. When compared with the general population, the absolute increase in fracture risk is moderately increased. In a population-based study, patients with PBC had a twofold increased risk of any fracture compared with the general population, with an absolute excess fracture rate of 12.5 per 1000 person-years [8].

        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Oct 15 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. American Gastroenterological Association. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology 2003; 125:937.
  2. Leslie WD, Bernstein CN, Leboff MS, American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125:941.
  3. Wariaghli G, Allali F, El Maghraoui A, Hajjaj-Hassouni N. Osteoporosis in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2010; 22:1397.
  4. Menon KV, Angulo P, Weston S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35:316.
  5. Springer JE, Cole DE, Rubin LA, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118:145.
  6. Guañabens N, Cerdá D, Monegal A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010; 138:2348.
  7. Mounach A, Ouzzif Z, Wariaghli G, et al. Primary biliary cirrhosis and osteoporosis: a case-control study. J Bone Miner Metab 2008; 26:379.
  8. Solaymani-Dodaran M, Card TR, Aithal GP, West J. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 2006; 131:1752.
  9. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995; 108:276.
  10. Matloff DS, Kaplan MM, Neer RM, et al. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982; 83:97.
  11. Guañabens N, Parés A, Ros I, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005; 42:573.
  12. Rosen H. Primary biliary cirrhosis and bone disease. Hepatology 1995; 21:253.
  13. Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987; 7:137.
  14. Fogelman I, Ryan P. Measurement of bone mass. Bone 1992; 13 Suppl 1:S23.
  15. Camisasca M, Albisetti W, Grandinetti G, et al. Bone disease in primary biliary cirrhosis (PBC): A large scale prevalence study (abstract). Eur J Gastroenterol Hepatol 1991; 3:526.
  16. Hodgson SF, Dickson ER, Wahner HW, et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985; 103:855.
  17. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795.
  18. Bingham CT, Fitzpatrick LA. Noninvasive testing in the diagnosis of osteomalacia. Am J Med 1993; 95:519.
  19. Hamburg SM, Piers DA, van den Berg AP, et al. Bone mineral density in the long term after liver transplantation. Osteoporos Int 2000; 11:600.
  20. Newton J, Francis R, Prince M, et al. Osteoporosis in primary biliary cirrhosis revisited. Gut 2001; 49:282.
  21. Menon KV, Angulo P, Boe GM, Lindor KD. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol 2003; 98:889.